Titan Pharmaceuticals Statistics Share Statistics Titan Pharmaceuticals has 1.33M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 1.33M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) 1.61% Shares Floating 947.41K Failed to Deliver (FTD) Shares 13,127 FTD / Avg. Volume 27.83%
Short Selling Information The latest short interest is 27.11K, so 2.04% of the outstanding
shares have been sold short.
Short Interest 27.11K Short % of Shares Out 2.04% Short % of Float 4.05% Short Ratio (days to cover) 1.6
Valuation Ratios The PE ratio is -0.62 and the forward
PE ratio is 0.24.
Titan Pharmaceuticals's PEG ratio is
0.02.
PE Ratio -0.62 Forward PE 0.24 PS Ratio 0 Forward PS 0.2 PB Ratio 1.2 P/FCF Ratio -0.76 PEG Ratio 0.02
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Titan Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 6.05,
with a Debt / Equity ratio of 0.
Current Ratio 6.05 Quick Ratio 6.05 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.18M Employee Count 4 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -26.42% in the
last 52 weeks. The beta is 1.42, so Titan Pharmaceuticals's
price volatility has been higher than the market average.
Beta 1.42 52-Week Price Change -26.42% 50-Day Moving Average 4.43 200-Day Moving Average 4 Relative Strength Index (RSI) 43.08 Average Volume (20 Days) 47,169
Income Statement
Revenue n/a Gross Profit -5K Operating Income -4.56M Net Income -4.71M EBITDA -4.7M EBIT -4.71M Earnings Per Share (EPS) -5.23
Full Income Statement Balance Sheet The company has 2.83M in cash and 0 in
debt, giving a net cash position of 2.83M.
Cash & Cash Equivalents 2.83M Total Debt n/a Net Cash n/a Retained Earnings -396.54M Total Assets 3.05M Working Capital 2.79M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -3.88M
and capital expenditures 0, giving a free cash flow of -3.88M.
Operating Cash Flow -3.88M Capital Expenditures n/a Free Cash Flow -3.88M FCF Per Share -4.32
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields TTNP does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for TTNP.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jan 9, 2024. It was a
backward
split with a ratio of 1:20.
Last Split Date Jan 9, 2024 Split Type backward Split Ratio 1:20
Scores Altman Z-Score -168.78 Piotroski F-Score 1
